Patents by Inventor Dennis G. Macejak

Dennis G. Macejak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions, methods and uses for improved human papilloma virus constructs
    Patent number: 11185580
    Abstract: Embodiments of the present invention provide compositions and methods for recombinantly generating tagless constructs of proteins or peptides. In certain embodiments, recombinant proteins or peptides disclosed herein concern human papilloma virus (HPV). Other embodiments concern using these constructs in compositions to elicit immune responses in a subject to one or more HPV types. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infections are also disclosed. Nucleic acids and expression vectors coding for constructs contemplated herein are provided. In certain embodiments, an HPV capsid protein generated is devoid of any fusion tags. In addition, truncated forms of HPV L1 are contemplated.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: November 30, 2021
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Robert L. Garcea, Dennis G. Macejak
  • COMPOSITIONS, METHODS AND USES FOR IMPROVED HUMAN PAPILLOMA VIRUS CONSTRUCTS
    Publication number: 20200121779
    Abstract: Embodiments of the present invention provide compositions and methods for recombinantly generating tagless constructs of proteins or peptides. In certain embodiments, recombinant proteins or peptides disclosed herein concern human papilloma virus (HPV). Other embodiments concern using these constructs in compositions to elicit immune responses in a subject to one or more HPV types. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infections are also disclosed. Nucleic acids and expression vectors coding for constructs contemplated herein are provided. In certain embodiments, an HPV capsid protein generated is devoid of any fusion tags. In addition, truncated forms of HPV L1 are contemplated.
    Type: Application
    Filed: August 2, 2019
    Publication date: April 23, 2020
    Inventors: ROBERT L. GARCEA, DENNIS G. MACEJAK
  • Compositions, methods and uses for improved human papilloma virus constructs
    Patent number: 10413603
    Abstract: Embodiments of the present invention provide compositions and methods for recombinantly generating tagless constructs of proteins or peptides. In certain embodiments, recombinant proteins or peptides disclosed herein concern human papilloma virus (HPV). Other embodiments concern using these constructs in compositions to elicit immune responses in a subject to one or more HPV types. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infections are also disclosed. Nucleic acids and expression vectors coding for constructs contemplated herein are provided. In certain embodiments, an HPV capsid protein generated is devoid of any fusion tags. In addition, truncated forms of HPV L1 are contemplated.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: September 17, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Robert L. Garcea, Dennis G. Macejak
  • HUMAN PAPILLOMA VIRUS CONSTRUCTS
    Publication number: 20170326224
    Abstract: Embodiments of the present invention provide compositions and methods for recombinantly generating tagless constructs of proteins or peptides. In certain embodiments, recombinant proteins or peptides disclosed herein concern human papilloma virus (HPV). Other embodiments concern using these constructs in compositions to elicit immune responses in a subject to one or more HPV types. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infections are also disclosed. Nucleic acids and expression vectors coding for constructs contemplated herein are provided. In certain embodiments, an HPV capsid protein generated is devoid of any fusion tags. In addition, truncated forms of HPV L1 are contemplated.
    Type: Application
    Filed: June 19, 2015
    Publication date: November 16, 2017
    Inventors: Robert L. Garcea, Dennis G. Macejak
  • Method of isolating ribozyme targets
    Patent number: 5496698
    Abstract: Method for in vivo selection of a ribozyme active at a defined RNA target.
    Type: Grant
    Filed: December 7, 1992
    Date of Patent: March 5, 1996
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Kenneth G. Draper, Dennis G. Macejak